Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests ...

Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be used to treat obesity and metabolic diseases ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

The FDA has cleared its first completely at-home sexual health test for women, available over-the-counter to screen for ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...

The federal government is cutting 3,500 full-time FDA employees and 1,200 NIH workers as part of an overarching move designed ...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. | ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

The restructuring is only the latest round of layoffs to hit Arbutus after the company shed 40% of its staff and cut back on ...